The group’s principal activities include acquiring, developing and seeking to Commercialize novel compounds to treat various types of cancer. The group products include RP101, Pentrys (TM), and GP1- 0100,Revisys (TM). The group marketed its products under the trade name Pentrys(TM). The group operates from the United States and Australia.